Stock Market News
GlaxoSmithKline's Relvar Ellipta gets updated label in EU
GlaxoSmithKline and its partner Innoviva announced on Thursday that the European Commission has approved a label update for the use of once-daily Relvar Ellipta (fluticasone furoate/vilanterol, FF/VI).
The FTSE 100 drugmaker said Relvar Ellipta is an inhaled corticosteroid and long-acting β2-agonist combination, with the label update for patients whose asthma was already adequately controlled on both an inhaled corticosteroid and long-acting β2-agonist.
It said the Type II variation regulatory approval was supported by data from a non-inferiority lung function study, which demonstrated that patients with adequately controlled asthma were able to switch to the once-daily FF/VI 100/25, from the twice-daily Seretide Accuhaler (fluticasone propionate /salmeterol) 250/50, without compromising their lung function.
No new safety signals were identified, and the adverse event data was said to be consistent with the known safety profile for FF/VI established in patients with asthma.
"Patients with asthma can continue to experience symptoms despite being adequately controlled and these symptoms can impact their lives," said GlaxoSmithKline senior vice-president and head of global respiratory franchise Jonathan Sweeting.
"This label update gives doctors the option of switching appropriate patients from their current ICS/LABA to once-daily Relvar Ellipta."
Dr Theodore J Witek Jr, senior vice-president and chief scientific officer of Innoviva, added that the evidence supporting the regulatory update meant doctors could be confident that patients taking once-daily Relvar Ellipta would experience "comparable benefit" in lung function and safety profile, as with a twice-daily ICS/LABA.
"We welcome this approval, which signifies an important milestone for Relvar Ellipta," Dr Witek added.
The updated marketing authorisation by the European Commission would be reflected on the label for Relvar Ellipta for countries in the European Union.
The FTSE 100 drugmaker said Relvar Ellipta is an inhaled corticosteroid and long-acting β2-agonist combination, with the label update for patients whose asthma was already adequately controlled on both an inhaled corticosteroid and long-acting β2-agonist.
It said the Type II variation regulatory approval was supported by data from a non-inferiority lung function study, which demonstrated that patients with adequately controlled asthma were able to switch to the once-daily FF/VI 100/25, from the twice-daily Seretide Accuhaler (fluticasone propionate /salmeterol) 250/50, without compromising their lung function.
No new safety signals were identified, and the adverse event data was said to be consistent with the known safety profile for FF/VI established in patients with asthma.
"Patients with asthma can continue to experience symptoms despite being adequately controlled and these symptoms can impact their lives," said GlaxoSmithKline senior vice-president and head of global respiratory franchise Jonathan Sweeting.
"This label update gives doctors the option of switching appropriate patients from their current ICS/LABA to once-daily Relvar Ellipta."
Dr Theodore J Witek Jr, senior vice-president and chief scientific officer of Innoviva, added that the evidence supporting the regulatory update meant doctors could be confident that patients taking once-daily Relvar Ellipta would experience "comparable benefit" in lung function and safety profile, as with a twice-daily ICS/LABA.
"We welcome this approval, which signifies an important milestone for Relvar Ellipta," Dr Witek added.
The updated marketing authorisation by the European Commission would be reflected on the label for Relvar Ellipta for countries in the European Union.
Related share prices |
---|
GlaxoSmithKline (GSK) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price